Diagnoses of major depression in 152 cancer patients differed as much as 13% depending on the diagnostic system used. The Beck Depression Inventory and the Hamilton Rating Scale for Depression were useful tools for screening patients with depressive symptoms but frequently misclassified those who had no major depression according to one or more of the criteria-based diagnostic systems.
"One study reported the prevalence of depression as 43% in which 19% had major depression and 24% had mild to moderate depression . Another study revealed the overall depression of 46% in which 20% of the patients had severe and clinical depression . However, in our study, the overall prevalence of depression according to BDI was 26.5% and all of them had mild to moderate scores (11-17), and we did not observe any patients with severe depression. "
[Show abstract][Hide abstract] ABSTRACT: Background
The symptoms related to depression in patients with cancer are amajor problem and could influence the treatment and survival of patients. This disorder is varied in different populations and in different studies.
We evaluated the prevalence of depression with Beck Depression Inventory (BDI) scale in 400 patients with cancer. This measurement was after the diagnosis of malignancy and before chemotherapy or radiotherapy.
The mean age of patients was 45 ±8.5 years, and female to male ratio was 45/55. The prevalence of depression was 24.8 % and 28% in males and females. All patients with depression had mild to moderate depression. Prevalence of depression was significantly higher in younger cases (P<0.0001). According to the site of malignancy, prevalence of depression was significantly highest in patients with breast cancer, following metastatic of unknown origin and gastrointestinal cancer and the lowest prevalence was observed in patients with hematologic malignancy (p <0.0001). Also, we observed a significant higherprevalence of depression in single versus married patients (p <0.0001), in patients with higher education (p <0.0001) and patients who had knowledge about their disease in comparison with those who had no knowledge (p <0.0001).
The prevalence of depression and its severity in cancer patients in South east of Iran was lower than other studies and it seems that this situation may be related to high religious beliefs in this region, high prevalence of illiteracy and lack of knowledge about their underlying disease.
Iranian Journal of Cancer Prevention 03/2013; 6(1):12-6.
"Cela était essentiellement dû aux diverses conceptualisations de la dépression et en particulier aux critères pour la définir, aux approches méthodologiques pour la mesurer et à la diversité des populations de patients étudiés (ambulatoire, hospitalisé) et des tumeurs considérées (localisation et stade). Ainsi, deux biais majeurs ont pu être relevés : • soit considérer les symptômes dépressifs comme un phénomène général (confondre symptômes dépressifs et syndrome dépressif majeur) ; • soit considérer les troubles dépressifs spécifiques définis par des critères diagnostiques selon une nosographie bien précise dans une perspective de recherche  . "
[Show abstract][Hide abstract] ABSTRACT: The purpose of this paper was to make a brief review of the main problematics raised by depression in oncology in terms of prevalence, semiology, screening, risk, prognosis factors and treatment. This reflection was based on recent literature data obtained through a PubMed search. Depressive disorders have frequently been encountered in cancer patients. During routine oncology daily care, depression screening, assessment and treatment are of paramount importance regarding psychosocial management. Depressive elements have a tremendous impact on the quality of life, tolerance and compliance with anticancer treatment. Moreover, depression morbidity and its possible influence on prognosis represent an important challenge in terms of prevention. A specific semiology for depressive disorders in the oncologic field might be more relevant with practical clinical implications. Optimal care of these mood disorders have to be implemented as soon as possible and be supported by the association of pharmacological treatment and psychotherapy.
"HAMD-24 contains 24 items which are recalled within the modified HAMD version of 1985 . But HAMD as well as CPRS (Comprehensive Psychopathological Rating Scale) or MADRS (Montgomery-Asberg Depression Rating Scale) are in fact no adequate diagnostic instruments for depression but measures of illness severity and it is still debatable whether these rating scales are suitable for primary identification of major depression [11,35-37]. In cancer patients diagnosis of depression requires special effort because somatic symptoms of depression like fatigue, anorexia and weight loss are quite common in malignancies. "
[Show abstract][Hide abstract] ABSTRACT: Various studies reported remarkable high incidence rates of depression in cancer patients compared with the general population. Pancreatic cancer is still one of the malignancies with the worst prognosis and therefore it seems quite logical that it is one of the malignancies with the highest incidence rates of major depression.However, what about the scientific background of this relationship? Is depression in patients suffering from pancreatic cancer just due to the confrontation with a life threatening disease and its somatic symptoms or is depression in this particular group of patients a feature of pancreatic cancer per se?
Several studies provide evidence of depression to precede the diagnosis of pancreatic cancer and some studies even blame it for its detrimental influence on survival. The immense impact of emotional distress on quality of life of cancer patients enhances the need for its early diagnosis and adequate treatment. Knowledge about underlying pathophysiological mechanisms is required to provide the optimal therapy.
A review of the literature on this issue should reveal which are the facts and what is myth.
BMC Cancer 10/2010; 10(1):569. DOI:10.1186/1471-2407-10-569 · 3.36 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.